These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
658 related articles for article (PubMed ID: 27127105)
1. PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research. Gadducci A; Guerrieri ME Anticancer Res; 2016 May; 36(5):2055-64. PubMed ID: 27127105 [TBL] [Abstract][Full Text] [Related]
3. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations. Miller RE; Ledermann JA Clin Adv Hematol Oncol; 2016 Sep; 14(9):704-11. PubMed ID: 27673289 [TBL] [Abstract][Full Text] [Related]
4. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594 [TBL] [Abstract][Full Text] [Related]
5. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer. Tewari KS; Eskander RN; Monk BJ Clin Cancer Res; 2015 Sep; 21(17):3829-35. PubMed ID: 26169965 [TBL] [Abstract][Full Text] [Related]
6. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis. Chung C; Lee R J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817 [TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different? Tan DS; Kaye SB Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149 [TBL] [Abstract][Full Text] [Related]
9. Rucaparib: a novel PARP inhibitor for Colombo I; Lheureux S; Oza AM Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854 [TBL] [Abstract][Full Text] [Related]
10. [Abnormalities of DNA repair and gynecological cancers]. Auguste A; Leary A Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544 [TBL] [Abstract][Full Text] [Related]
11. The current status of PARP inhibitors in ovarian cancer. McLachlan J; George A; Banerjee S Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873 [TBL] [Abstract][Full Text] [Related]
12. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review. Lau CH; Seow KM; Chen KH Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700 [TBL] [Abstract][Full Text] [Related]
13. A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy. Zhang N; Zheng H; Gao Y; Shu T; Wang H; Cai Y J Ovarian Res; 2024 Mar; 17(1):55. PubMed ID: 38444005 [TBL] [Abstract][Full Text] [Related]
14. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy. Lorusso D; Tripodi E; Maltese G; Lepori S; Sabatucci I; Bogani G; Raspagliesi F Drug Des Devel Ther; 2018; 12():1501-1509. PubMed ID: 29881257 [TBL] [Abstract][Full Text] [Related]
15. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488 [TBL] [Abstract][Full Text] [Related]
16. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy]. Schreiber V; Illuzzi G; Héberlé E; Dantzer F Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693 [TBL] [Abstract][Full Text] [Related]
17. PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic. Gadducci A; Guerrieri ME Crit Rev Oncol Hematol; 2017 Jun; 114():153-165. PubMed ID: 28477743 [TBL] [Abstract][Full Text] [Related]
18. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760 [TBL] [Abstract][Full Text] [Related]
19. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance. Oda K; Tanikawa M; Sone K; Mori-Uchino M; Osuga Y; Fujii T Int J Clin Oncol; 2017 Aug; 22(4):611-618. PubMed ID: 28508305 [TBL] [Abstract][Full Text] [Related]
20. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review. Cook SA; Tinker AV BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]